文献速递糖尿病

精准医学重新定义胰岛素分泌与单基因糖尿病(PRISM):中国年轻起病糖尿病患者的随机对照试验

Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes.
PubMed 文献 · Diabetes Care · 2026-01-01

PRISM 为单中心、双臂、3 年随机对照试验,纳入 884 例 18 至 50 岁、诊断年龄≤40 岁的中国非 1 型糖尿病患者。干预组接受技术引导评估与生物遗传标志物分型,并据此进行 1 年强化算法治疗及两次年度多学科复核。3 年时主要复合终点两组差异无统计学意义,但干预组达到三项及以上治疗目标的比例更高。

要点

  • 技术增强的多组分精准管理未降低糖尿病相关并发症复合终点。
  • 干预组达到三项及以上治疗目标的比例显著高于常规诊疗组。
  • 干预组 β 细胞功能替代指标改善且情绪困扰减少。

核心结论

  • 3 年技术增强多组分项目改善年轻起病糖尿病患者的代谢状况、β 细胞功能替代指标与患者报告结局,但未减少并发症。

研究设计与样本

  • 单中心、双臂、3 年随机对照试验,884 例中国 18 至 50 岁非 1 型糖尿病且诊断年龄≤40 岁患者,随机分为 JADE-PRISM 组(n=441)与 JADE-only 组(n=443)。

主要发现

  • 主要复合终点在 JADE-PRISM 组 116 例(26.3%)、JADE-only 组 125 例(28.2%),比值比 0.908(95%CI 0.675-1.221)。
  • JADE-PRISM 组 104 例(23.8%)对比 JADE-only 组 54 例(12.2%)达到三项及以上治疗目标,P<0.001。
  • JADE-PRISM 组 β 细胞功能替代指标改善且情绪困扰减少。

关键数值与推荐

  • 达到三项及以上治疗目标定义为 HbA1c<6.2%、血压<120/75 mmHg、LDL 胆固醇<1.2 mmol/L、甘油三酯<1.2 mmol/L、腰围女性<80 cm 或男性<85 cm。

临床怎么用

  • 对年轻起病非 1 型糖尿病患者可采用生物遗传标志物分型并结合技术引导的强化算法治疗与多学科年度复核,以改善代谢控制与患者报告结局,但需认识到该策略未显示减少并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Young-onset type 2 diabetes (YOD) results from complex causes, calling for precision management. RESEARCH DESIGN AND METHODS: The Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM) study was a single-center, two-arm, 3-year randomized controlled trial in which Chinese individuals aged 18 to 50 years with non-type 1 diabetes diagnosed at age ≤40 years were randomly assigned to intervention (Joint Asia Diabetes Evaluation [JADE]-PRISM) or usual clinic-based care (JADE only). The intervention included technologically guided assessment and use of biogenetic markers (autoantibodies, C-peptide, and common and rare genetic variants) to classify diabetes for 1-year intensified, algorithm-based treatment followed by two annual reviews by an endocrinologist-led multidisciplinary team. The primary end point was a composite of incident or progression of all diabetes-related complications. Secondary end points included attainment of three or more treatment targets (HbA1c <6.2%, blood pressure <120/75 mmHg, LDL cholesterol <1.2 mmol/L, triglycerides <1.2 mmol/L, and waist circumference <80 [women] or <85 cm [men]), proxies of β-cell function, and patient-reported outcome measures (PROMs). RESULTS: During 2020 to 2021, 884 participants (mean [SD] age 40.7 [6.5] years; mean [SD] age at diagnosis 32.5 [6.8] years; autoantibody positivity [n = 46]; monogenic diabetes [n = 23]; C-peptide <200 pmol/L [n = 82]; central obesity [n = 699]; dyslipidemia [n = 669]; hypertension [n = 588]; albuminuria [n = 313]; insulin treated [n = 250]) were randomly assigned to the JADE-PRISM (n = 441) or JADE-only group (n = 443). During the 3-year study, the primary end point developed in 116 participants (26.3%) in the JADE-PRISM group versus 125 (28.2%) in the JADE-only group (odds ratio 0.908 [95% CI 0.675-1.221]). In the JADE-PRISM group, 104 participants (23.8%) versus 54 in the JADE-only group (12.2%; P < 0.001) reached three or more treatment targets, with improved proxies of β-cell function and reduced emotional distress. CONCLUSIONS: A 3-year technology-enhanced, multicomponent program improved cardiometabolic status, proxies of β-cell function, and PROMs in individuals with YOD but did not reduce complications.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Luk AOY, O CK, Fan B, et al. Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes. Diabetes Care. 2026. PMID: 42118608. doi:10.2337/dc26-0114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。